Form 4: Lyell Immunopharma Director Klausner Acquires 130,000 Stock Options

Director Richard Klausner reports acquisition of 130,000 stock options in Lyell Immunopharma, Inc.

Summary

• Richard Klausner, a director of Lyell Immunopharma, Inc., filed a Form 4 disclosing changes in beneficial ownership.
• The report indicates that Klausner acquired 130,000 stock options on May 15, 2025, with an exercise price of $0.4017.
• These options vest on the earlier of the next annual stockholder meeting after May 15, 2025, or the first anniversary of that date, contingent on continuous service.
• Klausner also directly owns 2,967,834 shares of common stock and indirectly owns 843,365 shares through various family trusts.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard disclosure of stock option grants to a director. The director's acquisition of options could be interpreted as a positive signal, but it's not definitively bullish.

Positives

• The acquisition of stock options by a director could be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The vesting of the options is contingent on future events (annual meeting or anniversary) and continuous service, indicating a long-term commitment.

Industry Context

Form 4 filings are standard disclosures for corporate insiders and provide transparency into their transactions in the company's securities.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment if viewed as a sign of confidence by a company director.

Key Dates

Keywords

Form 4, Lyell Immunopharma, Director, Stock Options, Beneficial Ownership, Klausner, LYEL